xMD Diagnostics is Diagnostic Equipment in United States that focus on enriches cells business. Founded in 2011. They cover business area such as developer, molecular diagnostic tool, research, clinical laboratory, procure, enriche, cell, interest, biopsy, downstream PCR, NGS, molecular testing, histology and cytology specimen, pathologist, oncologist, patient, cancer.
2011
( 13 years old in 2024 )
Enriches Cells
-
Sinai Hospital of Baltimore BioIncubator
2401 West Belvedere Avenue Schapiro Building, Suite 309
Annapolis, MD 21215-5216
United States
Private
developermolecular diagnostic toolresearchclinical laboratoryprocureenrichecellinterestbiopsydownstream PCRNGSmolecular testinghistology and cytology specimenpathologistoncologistpatientcancer
* We use standard office opening hours in near xMD Diagnostics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
XMD Diagnostics is Diagnostic Equipment business from United States that founded in 2011 (13 years old in 2024), xMD Diagnostics business is focusing on Enriches Cells.
xMD Diagnostics headquarter office and corporate office address is located in Sinai Hospital of Baltimore BioIncubator 2401 West Belvedere Avenue Schapiro Building, Suite 309 Annapolis, MD 21215-5216 United States.
xMD Diagnostics was founded in United States.
In 2024, xMD Diagnostics is currently focus on enriches cells sector.
Above is snippet of Google Trends for "enriches cells" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with xMD Diagnostics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
